Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...
The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback